Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masatsune Ogura

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Journal of Pharmacological Sciences|September 2, 2022
HDL, cholesterol efflux, and ABCA1: Free from good and evil dualismMasatsune Ogura
Journal of Atherosclerosis and Thrombosis|October 1, 2025
From Risk to Resilience: Transforming Perinatal Management for Women with FHMasatsune Ogura
Journal of Atherosclerosis and Thrombosis|September 25, 2024
Exploration ContinuesMasatsune Ogura
Expert Review of Cardiovascular Therapy|October 1, 2025
How can cholesterol efflux capacity be used as a risk factor for atherosclerotic cardiovascular disease?Masatsune Ogura
Journal of Cardiology|August 9, 2017
PCSK9 inhibition in the management of familial hypercholesterolemiaMasatsune Ogura
Journal of Cardiology|November 28, 2017
Author's replyMasatsune Ogura
Circulation Journal : Official Journal of the Japanese Circulation Society|June 7, 2021
Unresolved Issues Regarding Proper Intake of Omega-3 Fatty AcidsMasatsune Ogura
Journal of Atherosclerosis and Thrombosis|June 16, 2024
Obicetrapib: There is still Life in the CETP Inhibitor!Masatsune Ogura
Circulation Journal : Official Journal of the Japanese Circulation Society|March 31, 2024
Do You Prescribe PCSK9 Inhibitors Properly?Masatsune Ogura
Journal of Atherosclerosis and Thrombosis|February 22, 2021
The Reason is Still UnclearMasatsune Ogura
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Journal of Pharmacological Sciences|September 2, 2022
HDL, cholesterol efflux, and ABCA1: Free from good and evil dualismMasatsune Ogura
Journal of Atherosclerosis and Thrombosis|October 1, 2025
From Risk to Resilience: Transforming Perinatal Management for Women with FHMasatsune Ogura
Journal of Atherosclerosis and Thrombosis|September 25, 2024
Exploration ContinuesMasatsune Ogura
Expert Review of Cardiovascular Therapy|October 1, 2025
How can cholesterol efflux capacity be used as a risk factor for atherosclerotic cardiovascular disease?Masatsune Ogura
Journal of Cardiology|August 9, 2017
PCSK9 inhibition in the management of familial hypercholesterolemiaMasatsune Ogura
Journal of Cardiology|November 28, 2017
Author's replyMasatsune Ogura
Circulation Journal : Official Journal of the Japanese Circulation Society|June 7, 2021
Unresolved Issues Regarding Proper Intake of Omega-3 Fatty AcidsMasatsune Ogura
Journal of Atherosclerosis and Thrombosis|June 16, 2024
Obicetrapib: There is still Life in the CETP Inhibitor!Masatsune Ogura
Circulation Journal : Official Journal of the Japanese Circulation Society|March 31, 2024
Do You Prescribe PCSK9 Inhibitors Properly?Masatsune Ogura
Journal of Atherosclerosis and Thrombosis|February 22, 2021
The Reason is Still UnclearMasatsune Ogura
Pageof 10